Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is a neuroscience-focused biotechnology business dedicated to discovering and developing novel medicines for patients suffering from severe neurological, endocrine, and psychiatric disorders. The company's commercial products include INGREZZA (for the treatment of tardive dyskinesia), ONGENTYS (for Parkinson's disease), ORILISSA (for severe pain associated with endometriosis), and ORIAHNN (for uterine fibroids). NBIX developed ORILISSA and ORIAHNN in collaboration with AbbVie Inc.
Why should investors make an exit?
Valuation Methodology: EV/Sales Multiple Based Relative Valuation
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's FY1 trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
Stock Recommendation:
NBIX's share price has surged 17.40% in the past month and is currently leaning towards the lower band of the 52-week range of USD 71.88 to USD 111.75. We have valued the stock using the EV/Sales-based relative valuation methodology and arrived at a target price of USD 77.97.
Considering the company's declining net margins, weak liquidity profile, current valuation and associated risks, we recommend a "Sell" rating on the stock at the current price of USD 88.65, up 1.74% as of February 25, 2022, at 02:02 PM ET. Markets are trading in a highly volatile zone currently due to certain macro-economic issues and geopolitical tensions prevailing.
Three-Year Technical Price Chart (as of February 25, 2022, at 02:02 PM ET). Analysis by Kalkine Group
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.
Curis, Inc.
Curis, Inc. (NASDAQ: CRIS) is a biotechnology business dedicated to developing cancer medicines. Everidge, a treatment for advanced basal cell carcinoma, is its main product, which it commercializes in collaboration with Genentech and Roche. Other CRIS therapeutics under development include CI-8993, a monoclonal anti-VISTA antibody, and certain oral small molecule antagonists of immune checkpoints such as CA-170 (VISTA/PDL1 antagonist), CA-327 (TIM3/PDL1 antagonist), and CA-4948 (IRAK4 kinase inhibitor).
Why Should Investors Make An Exit?
Valuation Methodology: EV/Sales Multiple Based Relative Valuation
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's FY1 trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
Stock Recommendation:
CRIS' share price has declined 77.78% in the past nine months and is currently leaning towards the lower band of the 52-week range of USD 2.78 to USD 17.40. We have valued the stock using the EV/Sales-based relative valuation methodology and arrived at a target price of USD 2.71.
Considering the significant dip in the stock price, declining fundamentals, current valuation and associated risks, we recommend a "Sell" rating on the stock at the closing price of USD 3.20, up 0.95% as of February 25, 2022. Markets are trading in a highly volatile zone currently due to certain macro-economic issues and geopolitical tensions prevailing.
Three-Year Technical Price Chart (as of February 25, 2022). Analysis by Kalkine Group
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.